Using Healthcare Claims Data to Identify Health Disparities for Individuals with Diagnosed and Undiagnosed Familial Hypercholesterolemia

Mary P. McGowan, Chao Xing, Amit Khera, Chun-Yuan Huang, Yanqiu Shao, Michelle Xing, Eric J. Brandt, Diane E. MacDougall, Catherine D. Ahmed, Katherine A. Wilemon, Zahid Ahmad
doi: https://doi.org/10.1101/2024.07.26.24311087

Abstract

Background Individuals with familial hypercholesterolemia (FH) require intensive lipid-lowering therapy, starting with high-intensity statins and adding ezetimibe and PCSK9 inhibitors (PCSK9i) as needed to reach target LDL-C levels. There are limited data on disparities in the use of these therapies among individuals with FH in the US.

Methods We queried a large US healthcare claims repository consisting of 324 million individuals, focusing on prescriptions for high-intensity statins, ezetimibe, and PCSK9i in two patient groups: those diagnosed with FH (ICD-10 E.78.01) and those not diagnosed with FH but identified as having probable FH (PFH) via the FIND-FH® machine learning algorithm. We used multivariable regression models to examine correlations with demographic/socioeconomic variables.

Results In the FH cohort (n = 85,457), 45.9% were female, 79.4% identified as White, 12.2% Black, and 8.4% as Hispanic. In the PFH cohort (n = 287,580), 42.2% were female, 78.2% White, 13.7% as Black, and 8.1% as Hispanic. Males were more likely to be prescribed high-intensity statins than females: odds ratio (OR) [95% confidence interval (CI)] = 2.05 [1.97, 2.13] and 1.60 [1.56,1.63] in the FH and the PFH cohorts, respectively. In both cohorts, White individuals were more likely to get ezetimibe, PCSK9i, or combination therapy compared to Black individuals (ORs: 1.12-1.40). Higher income was associated with increased odds of receiving these treatments (OR: 1.17-1.59 for incomes >$50,000). Higher education was linked to a higher likelihood of combination therapy (ORs [95% CI] = 1.49 [1.33, 1.68] and 1.18 [1.10, 1.27] in the FH and PFH cohorts, respectively).

Conclusions Real-world data indicate that more aggressive lipid-lowering therapy (ezetimibe and PCSK9i) is more often prescribed to White individuals, individuals with higher income, or those with advanced education, highlighting the need to improve equity in cardiovascular risk reduction for all individuals with FH.

What is new?

  • Health disparities exist for individuals with FH, regardless of whether they’ve been diagnosed.

  • The use of ezetimibe and PCSK9i is more likely to occur in individuals who are White, higher income, and advanced education.

What are the clinical Implications

  • Addressing health disparities in FH requires a multifaceted approach, including systemic changes to reduce bias in healthcare systems.

  • Ensuring equitable access to expensive lipid medications, such as PCSK9 inhibitors, is crucial for individuals from lower socioeconomic groups.

  • Providing access to case managers and geneticists can enhance health education and support, ultimately improving treatment outcomes for individuals with FH.

Introduction

Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by severe elevations in low-density lipoprotein cholesterol (LDL-C) from birth. Individuals with FH are at significantly increased risk for atherosclerotic cardiovascular disease (ASCVD), and aggressively reducing LDL-C levels through lipid-lowering drugs can mitigate this escalated ASCVD risk.1

The 2018 multi-society cholesterol guidelines recommend first-line treatment with high-intensity statins and, as needed, the addition of ezetimibe and PCSK9 inhibitors (PCSK9i) to achieve an LDL-C target of <100 mg/dL for primary prevention or a <70 mg/dL for secondary prevention.2 However, less than half of individuals with FH attain treatment goals. 3,4

We previously identified health disparities in LDL-C goal attainment and statin usage from specialized US lipid clinics within the CASCADE-FH® (CAscade SCreening for Awareness and DEtection) registry, a nationwide initiative of the Family Heart Foundation to profile treatment trends and track clinical and patient-reported outcomes in FH patients.5 We observed that women were less likely than men to receive high-intensity statin therapy, and non-Hispanic Black (“Black”) individuals were less likely than non-Hispanic White (“White”) individuals to meet LDL-C treatment targets, despite the former being more likely to receive high-intensity statins. However, it remains uncertain whether comparable disparities 1) extend to the wider US FH population, 2) include the use of ezetimibe and PCSK9i, and 3) relate to socioeconomic factors. Examining socioeconomic factors is especially crucial, as misguided beliefs about the biological basis of race have increased health care disparities.

We hypothesized that certain subpopulations, often from marginalized demographic or socioeconomic backgrounds, such as women, non-White individuals, those with limited educational attainment, and lower income levels, may be less likely to receive more aggressive lipid-lowering treatments (i.e., ezetimibe and PCSK9i) crucial for FH management. Such disparities would be concerning due to FH’s impact across all racial and ethnic groups and the elevated risk of premature ASCVD in women with FH, even during their reproductive years.

Methods

Study population

For the data included in our analyses, we queried the Family Heart Database™. This database comprises diagnostic, procedural, and prescription data derived from claims and/or laboratory records, encompassing a vast cohort of over 324 million individuals within the United States. The data in the Family Heart Database™ used for our analyses were sourced from Symphony Health (ICON plc Company, Blue Bell, PA), as previously described.6 For the current analysis, the dataset spanned from Sept 1, 2016 to Jun 30, 2020 and consisted of more than 77 million individuals with adequate prescription data covering the preceding six years.

Inclusion criteria for this study comprised of individuals meeting either of two conditions: those with a diagnosis of FH, defined by an ICD-10 diagnosis code of E.78.01, or those with undiagnosed FH, referred to as “probable FH” (PFH) as identified by the previously validated FIND FH® machine learning model developed by the Family Heart Foundation.7 Of note, that the FIND machine learning model excludes individuals with the ICD-10 E78.01 diagnostic code for FH.

Our analysis focused on examining filled prescriptions for high intensity statins, ezetimibe, and PCSK9i. The patients’ self-identified racial and ethnic classifications encompassed non-Hispanic Black (“Black”), non-Hispanic White (“White”), Hispanic, and the “Other” category. For the analyses described below, we opted to exclude the “Other” category - constituting of 3.30% and 3.25% of the patients in the FH and PFH cohorts, respectively – since this category included multiple ethnic/racial groups, potentially confounding associations between disparities in filled prescriptions and socioeconomic variables.

The dataset provided access to two key socioeconomic factors: education and household income. Education was divided into three levels: “high school graduate or less,” “some college,” and “associate / bachelor’s degree or higher.” Income was classified into three groups: “<$50K,” “$50-100K,” and “>$100K.”

Lipids lowering therapy categorization

Based on the analysis of filled prescriptions for statins, ezetimibe, and PCSK9i, patients within the LLT group were sorted into four distinct yet non-exclusive categories:

  1. High-Intensity statin: filled prescriptions for rosuvastatin at 20 or 40 mg per day or atorvastatin at 40 or 80 mg per day as defined by the 2018 Cholesterol Guidelines.8

  2. Ezetimibe: filled prescription for ezetimibe.

  3. PSCK9i: filled prescriptions for alirocumab or evolocumab administered either biweekly or monthly. (Inclisiran was not included as it was not approved until December 2021.)

  4. Statin + Ezetimibe + PCSK9i (“combination therapy”): filled prescriptions for statin along with ezetimibe and PCSK9i.

Statistical analysis

Data were summarized by count (proportion) for categorical variables and mean ± standard deviation for continuous variables. Comparisons among groups were made by t-test, ANOVA, and Pearson’s chi-squared test as appropriate. Multiple logistic regression models were fit with the binary LLT type as the dependent variable and the demographic and socioeconomic factors—race/ethnicity, age, sex, income, and education— as independent variables. Odds ratio (OR) and 95% confidence interval (CI) were reported. Analyses were performed in all individuals as well as in each racial/ethnic group, separately. We also performed sensitivity analysis in male and female patients, separately, and in three age groups: lower 50 percent, upper 50 percent, and interquartile range. All statistical analysis was performed using R (v4.2.1).

Results

Characteristics

Table 1 provides a summary of the demographic characteristics of patients categorized by racial and ethnic classification. There were 85,457 and 287,580 individuals In the FH and PFH cohorts, respectively. There were fewer Black individuals in the FH cohort than in the PFH cohort (12.2% vs. 13.7%; P<0.001). There were more females in the FH cohort than in the PFH cohort for all three ethnic groups (P’s<0.001). There was no significant difference between the two cohorts regarding education or income for Black and Hispanic groups. In contrast, the White group in the FH cohort tended to have lower education and income levels than those in the PFH group (P’s<0.005). The average age of patients in each subgroup was above 60 years old with the White group being the oldest group and Hispanic group the youngest in both cohorts (P’s<0.001). In each cohort, the White group displayed the highest levels of education and income (P’s<0.001).

View this table:
Table 1: Demographic distribution of familial hypercholesterolemia (FH) and probable familial hypercholesterolemia (PFH) patients receiving lipid lowering therapies stratified by race and ethnicity.

Differences in filled prescriptions between ethnic/racial groups

Table 2 presents the proportion of individuals across various types of LLT based on race and ethnicity. Figure 1 indicates the association of race and ethnicity with the filled prescription patterns of LLT as determined through multivariable analysis.

Figure 1:
Figure 1: Association of race and ethnicity with filled prescription for lipids lowering therapies

Multiple logistic regression models were fit with the binary lipids lowering therapy type as the dependent variable and ethnicity as the independent variable adjusting for age, sex, income, and education. The reference group was non-Hispanic Black. The FH cohort and PFH cohort were analyzed separately. Sample sizes are reported in Table 2. Odds ratio and 95% confidence interval were plotted.

View this table:
Table 2: Proportions of familial hypercholesterolemia (FH) and probable familial hypercholesterolemia (PFH) patients receiving lipid lowering therapies stratified by race and ethnicity

High-intensity statins

Within both FH and PFH, White individuals exhibited a decreased likelihood of receiving high-intensity statins when compared to Black individuals: ORs [95% CI] were 0.72 [0.68, 0.77] and 0.70 [0.67, 0.72] in the FH cohort and PFH cohort, respectively. There were no statistically significant distinctions between the Black and Hispanic groups.

Ezetimibe, PCSK9i, and combination therapy

In the FH cohort, White individuals were more likely to receive ezetimibe, PCSK9i, and the combination of statin+ezetimibe+PCSK9i treatments—ORs [95% CI] equal to 1.27 [1.20,1.34], 1.33 [1.22,1.44], and 1.22 [1.07,1.40], respectively—compared to Black individuals, whereas there was no statistical difference between Hispanics and Black individuals (Figure 1).

In the PFH cohort, White individuals were more likely to receive ezetimibe, PCSK9i, and the combination of statin+ezetimibe+PCSK9i treatments—ORs [95% CI] equal to 1.15 [1.12,1.18], 1.40 [1.35,1.46], and 1.12 [1.04,1.21], respectively—compared to Black individuals; Hispanic individuals were less likely to receive ezetimibe compared to Black individauls OR [95% CI] = 0.92 [0.88,0.96], but there was no significant difference for PCSK9i or the combination therapy (Figure 1).

Differences in filled prescriptions among income groups

High-intensity statins

As income levels increased, the OR of a filled prescription for high-intensity statins decreased (Figure 2). Relative to the “<$50K” income group, the ORs [95% CI] for receiving high-intensity statins were 0.77 [0.73, 0.81] and 0.61 [0.58, 0.65] for the “$50-100K” and “$>100K” income groups, respectively, within the FH cohort. These associations were consistently observed in the PFH cohort as well.

Figure 2:
Figure 2: Association of income levels with filled prescription for lipid lowering therapies

Multiple logistic regression models were fit with the binary lipids lowering therapy type as the dependent variable and income as the independent variable adjusting for age, sex, ethnicity, and education. The reference group was yearly income “<$50K”. The FH cohort and PFH cohort were analyzed separately. Sample sizes are reported in Table 2. Odds ratio and 95% confidence interval were plotted.

Ezetimibe, PCSK9i, and combination therapy

As income levels increased, the OR of a filled prescription increased for ezetimibe, PCSK9i, and the combination therapy (Figure 2). Compared to the “<$50K” income group, the ORs [95% CI] of receiving the three treatments were 1.17 [1.12,1.22], 1.30 [1.22-1.38], and 1.21 [1.09,1.35], respectively, for the “$50-100K” group, and 1.39 [1.33,1.46], 1.59 [1.47,1.71], and 1.45 [1.29,1.64] for the “>$100K” group in the FH cohort. These associations were consistently observed in the PFH cohort as well.

Differences in filled prescriptions among education groups

High-intensity statins

Higher education levels were linked to a lower likelihood of high-intensity statins prescription in the PFH cohort—Relative to the “high school graduate or less” group, the ORs [95% CI] for receiving high-intensity statins were 0.94 [0.90, 0.99] and 0.93 [0.88, 0.98] for the “some college” and “ associate / bachelor’s degree or more” groups, respectively. These associations were not statistically significant in the PFH cohort (Figure 3).

Figure 3:
Figure 3: Association of education levels with filled prescription for lipids lowering therapies

Multiple logistic regression models were fit with the binary lipids lowering therapy type as the dependent variable and education as the independent variable adjusting for age, sex, ethnicity, and income. The reference group was education level of “high school graduate or less”. The FH cohort and PFH cohort were analyzed separately. Sample sizes are reported in Table 2. Odds ratio and 95% confidence interval were plotted.

Ezetimibe, PCSK9i, and combination therapy

The likelihood of an individual getting a filled prescription for ezetimibe, PCSK9i, and the combination therapy increased with higher education levels. Within the “associate / bachelor’s degree or more” group, the ORs [95% CI] for receiving these treatments were as follows: 1.23 [1.17, 1.29] for ezetimibe, 1.21 [1.13, 1.30] for PCSK9i, and 1.50 [1.33, 1.68] for the combination therapy, relative to the “high school graduate or less” group in the FH cohort. This association remained significant for ezetimibe and the combination therapy in the PFH cohort, with ORs [95% CI] of 1.12 [1.09, 1.15] and 1.18 [1.10, 1.27], respectively.

Differences in filled prescriptions by gender

Males displayed a higher likelihood of obtaining filled prescriptions for high-intensity statins— ORs [95% CI] were 2.05 [1.97, 2.13] and 1.60 [1.56, 1.63] in the FH cohort and PFH cohort, respectively (Figure 4). In contrast, males exhibited a decreased likelihood of being prescribed ezetimibe, PCSK9i, and the combination therapy, with ORs [95% CI] of 0.65 [0.63, 0.67], 0.57 [0.54, 0.60], and 0.64 [0.69, 0.70], respectively, in the FH cohort, and ORs [95% CI] of 0.76 [0.74, 0.78], 0.83 [0.81, 0.85], and 0.86 [0.82, 0.90], respectively in the PFH cohorts.

Figure 4:
Figure 4: Association of gender with filled prescription for lipids lowering therapies

Multiple logistic regression models were fit with the binary lipids lowering therapy type as the dependent variable and sex as the independent variable adjusting for age, ethnicity, income, and education. The reference group was female. The FH cohort and PFH cohort were analyzed separately. Sample sizes are reported in Table 2. Odds ratio and 95% confidence interval were plotted.

Sensitivity analyses

Sensitivity analyses were performed in the subgroups stratified by race—White, Black, and Hispanics (Figures S1-S3), gender—males and females (Table S1), and age—lower 50 percent, upper 50 percent, and interquartile range (Table S2). Most of findings using the whole sample remained significant: White individuals were more likely to receive ezetimibe, PCSK9i, and the combination therapy than Black and Hispanic individuals; White individuals were less likely to receive high-intensity statins than Black individuals; males were more likely to receive high-intensity statins; the likelihood of being prescribed ezetimibe, PCSK9i, and the combination therapy all increased with higher education and greater income.

Discussion

We analyzed a healthcare claims database and found treatment disparities for FH patients in the US population with regards to filled prescription for high-intensity statins, ezetimibe, and PCSK9i. Our main finding is that that more aggressive lipid-lowering therapy (ezetimibe and PCSK9i) is more often prescribed to White individuals, individuals with higher income, or those with advanced education.

Our findings contribute to the existing body of knowledge concerning health disparities among individuals with FH. Prior work has mostly been done outside the US, limited to gender differences, and did not include individuals with FH who have yet to be diagnosed (PFH). In a FH cohort from British Columbia (n = 579), Ryzhaya et. al. also found women were less likely to be prescribed high-intensity statins (45% women vs 55% p=0.03).9 Unlike our findings, though, they found females were less likely to be prescribed ezetimibe; in addition, socioeconomic factors were not accounted for in their analyses. In a separate cohort of FH patients in Spain, PCSK9i use was uncommon (3.5%) – similar to our findings – and women were less frequently treated with high-intensity statins (OR [95% CI] = 0.62; 0.44-0.88) and PCSK9 inhibitors (OR [95% CI] = 0.56; 0.39-0.82).10

In the US population of individuals with FH, previous research has offered limited exploration of disparities beyond the scope of statin usage, and only a few studies have incorporated socioeconomic factors into their analyses. Although not specific to FH, a recent study from the US Veterans Affairs system identified 1,225 veterans with severe hypercholesterolemia (LDL-C above 190 mg/dL). Similar to our findings in women, their data showed females were more likely to be initiated on PCSK9i (OR 1.99; 1.03-3.87).11 However, it’s noteworthy that within this cohort of severe hypercholesterolemia patients in the Veterans Affairs system, factors such as ethnicity, race, and income level were not identified as significant determinants. This observation potentially reflects the specific patient population accessing care through the Veterans Affairs system, where different socioeconomic factors and structural determinants of health might be at play.

In comparison to the disparities observed in the general population, our findings for high-intensity statins differ from established patterns. Typically, research in the general population has revealed that cohorts who are Black or lower socioeconomic status tend to exhibit the lowest utilization of statins12–14. However, we previously found, among Black individuals with FH who get care at specialty lipid clinics, a higher chance of getting high-intensity statin therapy. 5 Our current study, in the broader US context of individuals with FH, replicates these finding and also identified lower socioeconomic status (income and education) as a predictor of high-intensity statins use. These differences between the general population and the FH population suggest that factors specific to FH may influence prescription patterns, resulting in unique disparities that deviate from broader trends. This emphasizes the importance of conducting targeted research within specific patient populations, such as FH, to gain a comprehensive understanding of the complexities surrounding health disparities and treatment practices.

In the general population, women are less likely to receive guideline-recommended statin therapy compared with men.15,16 This observed disparity has been attributed to a variety of factors including refusal of statin therapy, increased discontinuation of statin therapy, and potentially lower prescription rates of statin therapy by their healthcare providers.15,17–19 Our study’s findings introduce an additional potential explanation for this phenomenon: women, as a collective, might utilize ezetimibe and PCSK9i more so compared to men. It emphasizes the need for further investigation into the factors influencing these prescription patterns to ensure equitable and optimal cardiovascular care for all individuals.

Our findings of disparities associated with income levels are especially important since income is strongly associated with morbidity and mortality, and income-related health disparities appear to be growing. A systematic review and meta-analysis of 12 prospective cohort studies including 1,710,000 participants found that individuals with the lowest income had a 29% higher risk of cardiovascular disease compared to those with the highest income. Additionally, individuals with low income had a 46% higher risk of dying from cardiovascular disease compared to those with high income. The study concluded that low income is a significant risk factor for cardiovascular disease and related mortality.20 The mechanisms underlying the associations between income and education disparities and cardiovascular morbidity and mortality are complex and multifactorial. Social determinants of health, such as education, housing, employment, access to healthcare, and food insecurity are all interconnected and can influence health outcomes, including cardiovascular disease.21,22

Limitations

Despite the robustness of our study’s large sample size, several limitations warrant consideration. Notably, we were unable to account for statin intolerance, a plausible contributing factor in explaining the lower utilization of high-intensity statin therapy in women. Our dataset does not account for differences in ASCVD status. However, it is worth mentioning that prior research encompassing both statin intolerance and ASCVD status found negligible impact on similar overall findings for gender disparities.23 Furthermore, certain US healthcare systems, such as the Veterans Affairs and Kaiser Permanente systems, were not encompassed in our dataset. It is important to acknowledge that disparities in health treatment have been identified within these systems as well.11 Another potential limitation lies in the possibility of miscoding and errors in provider charting, which may have influenced our results. Our study lacked data pertaining to emerging lipid-lowering medications like inclisiran and bempedoic acid as well as laboratory findings. The absence of information on LDL-C levels restricts our capacity to comment on the achievement of LDL-C goal attainment. Lastly, it is worth noting that our dataset provided access to only a limited set of socioeconomic factors and did not encompass broader structural determinants of health which might play a significant role in health disparities. As such, our data cannot distinguish where these disparities occur in the life experience of FH and PFH patients. One cautionary note on interpreting the results is that the study is subject to collider bias, and therefore one should take caution inferring causality, though the correlations are robust, and the estimates could be biased.

Impact

As treatment of individuals with FH expands in the US, the disparities we identified may become more pronounced if not addressed. 24 Such gaps in lipid treatment have been associated with increased ASCVD morbidity and mortality - as well as increased healthcare expenditures.25,26 - especially affecting women, racial and ethnic minorities, and individuals of lower socioeconomic status. 5,13,27–29

Future work

Efforts to improve health disparities must take a multifaceted approach, including addressing systemic discrimination, ensuring equitable access to costly lipid medications, and providing access to case managers and geneticists for health education. Such efforts must consider more socioeconomic factors as well as social determinants of health.30,31

Conclusion/Summary

Real world patterns of medical care reveal lipid lowering therapies, particularly those extending beyond statins to include ezetimibe and PCSK9i, are more often prescribed for individuals with FH who are White, have high income, or received advanced education. Efforts are warranted to improve equity and provide all individuals with FH an opportunity for cardiovascular risk reduction.

Source of funding

none

Disclosures

ZA research funding from US Department of Defense, National Institute of Health, and Ionis Pharmaceuticals; Site Primary Investigator for Ionis Pharmaceuticals. AK: research funding from National Institute of Health

Data Availability

Data available by request, subject to approval by the Family Heart Foundation.

References

  1. 1.↵
    Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. NEJM. 2019/10/17 2019;381(16):1547–1556. doi:10.1056/NEJMoa1816454
    OpenUrlCrossRefPubMed
  2. 2.↵
    Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. Nov 3 2018;doi:10.1016/j.jacc.2018.11.002
    OpenUrlFREE Full Text
  3. 3.↵
    Duell PB, Gidding SS, Andersen RL, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis. Oct 2019;289:85–93. doi:10.1016/j.atherosclerosis.2019.08.007
    OpenUrlCrossRef
  4. 4.↵
    deGoma EM, Ahmad ZS, O’Brien EC, et al. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. Jun 2016;9(3):240–9. doi:10.1161/CIRCGENETICS.116.001381
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Amrock SM, Duell PB, Knickelbine T, et al. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. Atherosclerosis. Dec 2017;267:19–26. doi:10.1016/j.atherosclerosis.2017.10.006
    OpenUrlCrossRef
  6. 6.↵
    Cuchel M, Lee PC, Hudgins LC, et al. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. May 2 2023;12(9):e029175. doi:10.1161/JAHA.122.029175
    OpenUrlCrossRef
  7. 7.↵
    Banda JM, Sarraju A, Abbasi F, et al. Finding missed cases of familial hypercholesterolemia in health systems using machine learning. NPJ Digit Med. 2019;2:23. doi:10.1038/s41746-019-0101-5
    OpenUrlCrossRef
  8. 8.↵
    Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. Jun 25 2019;73(24):3168–3209. doi:10.1016/j.jacc.2018.11.002
    OpenUrlFREE Full Text
  9. 9.↵
    Ryzhaya N, Cermakova L, Trinder M, et al. Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia. J Am Heart Assoc. Jun 2021;10(11):e019286. doi:10.1161/JAHA.120.019286
    OpenUrlCrossRef
  10. 10.↵
    Zamora A, Ramos R, Comas-Cufi M, et al. Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men. Sci Rep. Jan 27 2023;13(1):1492. doi:10.1038/s41598-023-27963-z
    OpenUrlCrossRef
  11. 11.↵
    Derington CG, Colantonio LD, Herrick JS, et al. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association. Apr 20 2021;10(8):e019254. doi:10.1161/jaha.120.019254
    OpenUrlCrossRef
  12. 12.↵
    Jacobs JA, Addo DK, Zheutlin AR, et al. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol. May 1 2023;8(5):443–452. doi:10.1001/jamacardio.2023.0228
    OpenUrlCrossRef
  13. 13.↵
    Suero-Abreu GA, Karatasakis A, Rashid S, et al. Factors Associated with Disparities in Appropriate Statin Therapy in an Outpatient Inner City Population. Healthcare (Basel). Sep 24 2020;8(4) doi:10.3390/healthcare8040361
    OpenUrlCrossRef
  14. 14.↵
    Gamboa CM, Colantonio LD, Brown TM, Carson AP, Safford MM. Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc. May 10 2017;6(5)doi:10.1161/JAHA.116.004264
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Nanna MG, Wang TY, Xiang Q, et al. Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes. Aug 2019;12(8):e005562. doi:10.1161/CIRCOUTCOMES.118.005562
    OpenUrlCrossRefPubMed
  16. 16.↵
    Peters SAE, Colantonio LD, Zhao H, et al. Sex Differences in High-Intensity Statin Use Following Myocardial Infarction in the United States. J Am Coll Cardiol. Apr 24 2018;71(16):1729–1737. doi:10.1016/j.jacc.2018.02.032
    OpenUrlFREE Full Text
  17. 17.↵
    Brown CJ, Chang LS, Hosomura N, et al. Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk. JAMA Netw Open. Feb 1 2023;6(2):e231047. doi:10.1001/jamanetworkopen.2023.1047
    OpenUrlCrossRef
  18. 18.
    Olmastroni E, Boccalari MT, Tragni E, et al. Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategies. Pharmacol Res. May 2020;155:104514. doi:10.1016/j.phrs.2019.104514
    OpenUrlCrossRefPubMed
  19. 19.↵
    Witting C, Azizi Z, Gomez SE, et al. Natural language processing to identify reasons for sex disparity in statin prescriptions. Am J Prev Cardiol. Jun 2023;14:100496. doi:10.1016/j.ajpc.2023.100496
    OpenUrlCrossRef
  20. 20.↵
    Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. Jama. Mar 24 2010;303(12):1159–66. doi:10.1001/jama.2010.297
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    Brandt Eric J, Tobb K, Cambron Julia C, et al. Assessing and Addressing Social Determinants of Cardiovascular Health. Journal of the American College of Cardiology. 2023/04/11 2023;81(14):1368–1385. doi:10.1016/j.jacc.2023.01.042
    OpenUrlCrossRef
  22. 22.↵
    Brandt EJ, Chang T, Leung C, Ayanian JZ, Nallamothu BK. Food Insecurity Among Individuals With Cardiovascular Disease and Cardiometabolic Risk Factors Across Race and Ethnicity in 1999-2018. JAMA Cardiology. 2022;doi:10.1001/jamacardio.2022.3729
    OpenUrlCrossRef
  23. 23.↵
    Jiménez A, Viñals C, Marco-Benedí V, et al. Sex Disparities in Familial Hypercholesterolemia. J Am Coll Cardiol. Jan 17 2023;81(2):203–205. doi:10.1016/j.jacc.2022.10.023
    OpenUrlCrossRef
  24. 24.↵
    Khoury MJ, Bowen S, Dotson WD, et al. Health equity in the implementation of genomics and precision medicine: A public health imperative. Genet Med. Aug 2022;24(8):1630–1639. doi:10.1016/j.gim.2022.04.009
    OpenUrlCrossRef
  25. 25.↵
    Bui A, Kwon J, Kim J, Lucas A. Overcoming barriers to statin adherence. US Pharm. Jun 18 2019;44(6):19–22.
    OpenUrl
  26. 26.↵
    Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J Clin Lipidol. Jan-Feb 2017;11(1):70–79 e1. doi:10.1016/j.jacl.2016.10.003
    OpenUrlCrossRef
  27. 27.↵
    Metser G, Bradley C, Moise N, Liyanage-Don N, Kronish I, Ye S. Gaps and disparities in primary prevention statin prescription during outpatient care. Am J Cardiol. Dec 15 2021;161:36–41. doi:10.1016/j.amjcard.2021.08.070
    OpenUrlCrossRef
  28. 28.
    Ohm J, Skoglund PH, Habel H, et al. Association of socioeconomic status with risk factor target achievements and use of secondary prevention after myocardial infarction. JAMA network open. Mar 1 2021;4(3):e211129. doi:10.1001/jamanetworkopen.2021.1129
    OpenUrlCrossRef
  29. 29.↵
    Hero C, Karlsson SA, Franzen S, et al. Impact of socioeconomic factors and gender on refill adherence and persistence to lipid-lowering therapy in type 1 diabetes. Diabetes Ther. Sep 2021;12(9):2371–2386. doi:10.1007/s13300-021-01115-w
    OpenUrlCrossRef
  30. 30.↵
    Balla S, Ekpo EP, Wilemon KA, Knowles JW, Rodriguez F. Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care. Curr Atheroscler Rep. Aug 20 2020;22(10):60. doi:10.1007/s11883-020-00881-5
    OpenUrlCrossRefPubMed
  31. 31.↵
    Sharma J, McAlister J, Aggarwal NR, et al. Evaluation and management of blood lipids through a woman’s life cycle. Am J Prev Cardiol. Jun 2022;10:100333. doi:10.1016/j.ajpc.2022.100333
    OpenUrlCrossRef
Back to top
Posted July 29, 2024.
Download PDF
Data/Code
Email
Using Healthcare Claims Data to Identify Health Disparities for Individuals with Diagnosed and Undiagnosed Familial Hypercholesterolemia
Mary P. McGowan, Chao Xing, Amit Khera, Chun-Yuan Huang, Yanqiu Shao, Michelle Xing, Eric J. Brandt, Diane E. MacDougall, Catherine D. Ahmed, Katherine A. Wilemon, Zahid Ahmad
medRxiv 2024.07.26.24311087; doi: https://doi.org/10.1101/2024.07.26.24311087
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area